Idorsia (IDIA) Hisse Özeti
Bir biyofarmasötik şirketi olan Idorsia Ltd, İsviçre, Amerika Birleşik Devletleri, Japonya, Avrupa ve Kanada'da karşılanmamış tıbbi ihtiyaçlara yönelik ilaçların keşfi, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 0/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
+ 1 daha fazla risk
IDIA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Idorsia Ltd Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | CHF 4.13 |
| 52 Haftanın En Yüksek Seviyesi | CHF 4.85 |
| 52 Haftanın En Düşük Seviyesi | CHF 1.46 |
| Beta | 1.66 |
| 1 Aylık Değişim | 9.25% |
| 3 Aylık Değişim | 11.83% |
| 1 Yıllık Değişim | 166.58% |
| 3 Yıllık Değişim | -47.06% |
| 5 Yıllık Değişim | -83.18% |
| Halka arzdan bu yana değişim | -69.73% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • May 04
IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs
Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.Anlatı Güncellemesi • Apr 18
IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.Recent updates
Anlatı Güncellemesi • May 04
IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs
Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.Anlatı Güncellemesi • Apr 18
IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.Anlatı Güncellemesi • Apr 04
IDIA: Fabry Pipeline Progress Will Continue To Drive Future Upside
Analysts have trimmed their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts are still assigning upside potential to Idorsia shares even after the target reset to CHF 5, which signals that they see value at current levels despite near term headwinds.Anlatı Güncellemesi • Mar 20
IDIA: Fabry And Resistant Hypertension Progress Will Continue To Drive Future Upside
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent research points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern around execution and cost control.Anlatı Güncellemesi • Mar 05
IDIA: Fabry And Resistant Hypertension Progress Will Likely Drive Future Upside
Analysts have revised their CHF price targets for Idorsia to reflect updated assumptions for discount rates, revenue growth, profit margins and future P/E. They are now presenting a more balanced view of the company’s risk and earnings potential.Anlatı Güncellemesi • Feb 19
IDIA: Fabry And Hypertension Pipeline Advances Will Likely Drive Future Upside
Analysts have adjusted their CHF price target on Idorsia based on updated assumptions around discount rates, revenue, profit margins, and a higher expected future P/E multiple, resulting in a revised valuation framework in CHF terms. What's in the News Idorsia outlined an FDA-agreed Phase 3 registration program for lucerastat in Fabry disease, centered on kidney pathology and including a pivotal biopsy study plus a second trial comparing oral therapy with current standard-of-care to support a potential market authorization pathway (Key Developments).Anlatı Güncellemesi • Feb 04
IDIA: Hypertension And Insomnia Pipeline Progress Will Likely Drive Future Upside
Analysts have trimmed their price target on Idorsia to reflect a slightly lower profit margin outlook and a higher assumed future P/E of 31.60x, while keeping their fair value estimate broadly unchanged. What's in the News Idorsia signed an exclusive license and supply agreement with EMS S.A. to bring QUVIVIQ (daridorexant) to patients across Latin America.Anlatı Güncellemesi • Jan 21
IDIA: Hypertension And Insomnia Franchise Will Likely Drive Future Upside
Analysts have adjusted their price target on Idorsia slightly lower to reflect updated assumptions around fair value, a modestly higher discount rate, more conservative revenue growth expectations, a similar profit margin outlook, and a higher future P/E multiple. What's in the News Publication of Phase 3 MODIFY and open label extension data for lucerastat in Fabry disease, with results in Nature Communications highlighting sustained biomarker reductions and signals on renal and cardiac function in a small patient population.Anlatı Güncellemesi • Jan 07
IDIA: Hypertension And Insomnia Assets Will Likely Drive Future Upside
Analysts have kept their price target for Idorsia broadly unchanged. They cite only small tweaks to inputs such as a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a marginally adjusted future P/E multiple as the basis for their updated view.Analiz Makalesi • Dec 22
Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Idorsia Ltd ( VTX:IDIA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. The...Anlatı Güncellemesi • Dec 17
IDIA: Hypertension And Insomnia Portfolio Will Likely Deliver Upside From Current Levels
Analysts have raised their price target for Idorsia significantly, citing a higher fair value estimate of 5.0 dollars, stronger anticipated revenue growth, and an expectation of a materially higher future price to earnings multiple, partially offset by a slightly lower discount rate. What's in the News Idorsia reaffirmed 2025 guidance, targeting around CHF 130 million in QUVIVIQ net sales and a US-GAAP operating loss of about CHF 55 million for the global business, supported by approximately CHF 165 million EBIT from partnered activities (corporate guidance).Anlatı Güncellemesi • Dec 03
IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price
Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).Anlatı Güncellemesi • Nov 19
IDIA: Limited Near-Term Upside Expected Despite Recent Price Reassessment
Narrative Update on Idorsia Analysts have raised their price target for Idorsia, doubling it from CHF 1 to CHF 2. This change is attributed to improved outlooks in key financial metrics, including a slightly lower discount rate and stable revenue growth projections.Analiz Makalesi • Nov 07
Little Excitement Around Idorsia Ltd's (VTX:IDIA) Revenues As Shares Take 29% Pounding
The Idorsia Ltd ( VTX:IDIA ) share price has softened a substantial 29% over the previous 30 days, handing back much of...Anlatı Güncellemesi • Nov 03
IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift
Analysts have increased their price target for Idorsia by CHF 1.00 to CHF 2.00. They cite improved revenue growth projections and a more favorable future price-to-earnings outlook, despite a slightly higher discount rate and modestly lower profit margin expectations.Anlatı Güncellemesi • Sep 23
Global Expansion And FDA Review Will Moderate Overvaluation
Despite a decline in revenue growth forecasts, the significant rise in Idorsia’s future P/E multiple underpins the sharp increase in its consensus analyst price target from CHF2.00 to CHF4.00. What's in the News Simcere Pharmaceuticals launched QUVIVIQ (daridorexant), Idorsia's dual orexin receptor antagonist for insomnia, in China, with approval highlighting its differentiated clinical profile and lack of psychotropic labeling.Analiz Makalesi • Sep 14
Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Idorsia Ltd ( VTX:IDIA ) shares have continued their recent momentum with a 38% gain in the last month alone. The...Yeni Anlatı • Sep 08
Global Expansion And FDA Review Will Moderate Overvaluation
Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.Analiz Makalesi • Aug 24
New Forecasts: Here's What Analysts Think The Future Holds For Idorsia Ltd (VTX:IDIA)
Shareholders in Idorsia Ltd ( VTX:IDIA ) may be thrilled to learn that the covering analyst has just delivered a major...Analiz Makalesi • Jul 19
There's Reason For Concern Over Idorsia Ltd's (VTX:IDIA) Massive 46% Price Jump
Despite an already strong run, Idorsia Ltd ( VTX:IDIA ) shares have been powering on, with a gain of 46% in the last...Analiz Makalesi • Dec 19
Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Idorsia Ltd ( VTX:IDIA ) shareholders are no doubt pleased to see that the share price has bounced 71% in the last...Analiz Makalesi • Nov 06
One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts
The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the covering analyst making...Analiz Makalesi • Nov 04
Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower
To the annoyance of some shareholders, Idorsia Ltd ( VTX:IDIA ) shares are down a considerable 33% in the last month...Analiz Makalesi • Sep 18
Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper
The Idorsia Ltd ( VTX:IDIA ) share price has fared very poorly over the last month, falling by a substantial 25%. For...Analiz Makalesi • May 30
Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company
Idorsia Ltd ( VTX:IDIA ) shareholders would be excited to see that the share price has had a great month, posting a 26...Analiz Makalesi • May 26
Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year
The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the analysts making...Analiz Makalesi • May 01
Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%
The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the analysts making...Analiz Makalesi • Apr 05
Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts
Shareholders in Idorsia Ltd ( VTX:IDIA ) may be thrilled to learn that the analysts have just delivered a major upgrade...Analiz Makalesi • Mar 10
Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues
Idorsia Ltd ( VTX:IDIA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...Analiz Makalesi • Mar 08
Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Those holding Idorsia Ltd ( VTX:IDIA ) shares would be relieved that the share price has rebounded 38% in the last...Hissedar Getirileri
| IDIA | CH Biotechs | CH Pazar | |
|---|---|---|---|
| 7D | -7.1% | 1.8% | 1.8% |
| 1Y | 166.6% | 33.7% | 9.1% |
Getiri vs. Endüstri: IDIA geçen yıl % 33.7 oranında getiri sağlayan Swiss Biotechs sektörünü aştı.
Getiri vs Piyasa: IDIA geçen yıl % 9.1 oranında getiri sağlayan Swiss Piyasasını aştı.
Fiyat Oynaklığı
| IDIA volatility | |
|---|---|
| IDIA Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.4% |
İstikrarlı Hisse Senedi Fiyatı: IDIA hisse senedi fiyatı, son 3 ayda Swiss piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: IDIA 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala Swiss hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2017 | 456 | Jean-Paul Clozel | www.idorsia.com |
Bir biyofarmasötik şirketi olan Idorsia Ltd, İsviçre, Amerika Birleşik Devletleri, Japonya, Avrupa ve Kanada'da karşılanmamış tıbbi ihtiyaçlar için ilaçların keşfi, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Şirket, CNS, kardiyovasküler, immünolojik bozukluklar ve yetim hastalıklar gibi çeşitli terapötik alanlar için bir klinik geliştirme hattına sahiptir. Uykusuzluk tedavisi için QUVIVIQ (daridorexant) sunmaktadır.
Idorsia Ltd Temel Bilgiler Özeti
| IDIA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | CHF 1.05b |
| Kazançlar(TTM) | -CHF 111.70m |
| Gelir(TTM) | CHF 220.58m |
4.8x
P/S Oranı-9.4x
F/K OranıIDIA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| IDIA gelir tablosu (TTM) | |
|---|---|
| Gelir | CHF 220.58m |
| Gelir Maliyeti | CHF 123.12m |
| Brüt Kâr | CHF 97.46m |
| Diğer Giderler | CHF 209.16m |
| Kazançlar | -CHF 111.70m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
Jul 30, 2026
| Hisse başına kazanç (EPS) | -0.44 |
| Brüt Marj | 44.18% |
| Net Kâr Marjı | -50.64% |
| Borç/Özkaynak Oranı | -101.6% |
IDIA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 10:22 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Idorsia Ltd 10 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rosie Turner | Barclays |
| Alistair Campbell | Berenberg |
| Sachin Jain | BofA Global Research |